109 results about "Geneologies" patented technology

The invention provides a cell development process dynamic modeling method and device based on time sequence single cell transcriptome data and a medium, and relates to the crossing field of bioinformatics and computational biology. The method comprises the following steps: constructing a Shenchang differential equation learning framework; adjusting parameters of the single cell development state change model based on the Shenxuan differential equation learning framework so as to construct a population cell development state change model; obtaining a cell specific gene regulation network and a population cell gene regulation network based on the population cell development state change model so as to predict occurrence opportunity of cell lineage differentiation and a molecular decision mechanism of cell differentiation; therefore, the problems of incomplete modeling mechanism, insufficient noise processing and lack of energy principle in the existing cell development process are solved.

The invention relates to a method for inducing mouse trophoblast stem cells in vitro. According to the method, mouse embryonic stem cells are used as starting cells, Sorcs3 gene knockout mouse embryonic stem cells are obtained through a gene editing technology, and in-vitro induced trophoblast stem cells (iTSCs) are efficiently and rapidly obtained by means of a flow cytometry sorting technology and in combination with specific antibody sorting. According to the invention, the Sorcs3 gene is knocked out from the embryonic stem cell, so that the capability of the embryonic stem cell to differentiate to the trophoblast lineage can be obviously enhanced; an important research platform is provided for deeply researching a lineage intertransformation mechanism of cell masses (ICM) and trophoblast (TE) in the blastocysts, and the method has important significance for researching lineage limitation of early embryonic development of mammals and the like.

The invention provides a non-lineage animal pairing evaluation method based on genome data, and belongs to the technical field of bioinformatics and protection genetics, the method comprises the following steps: firstly, obtaining whole genome sequencing data of all individuals in a population, and carrying out quality control to obtain a high-quality SNP site set; aiming at all possible male and female pairing combinations in the population, calculating an inter-parent genetic coefficient depKin, an inter-parent heterozygous difference ratio HDR and an inter-parent potential risk load index GRLI, and predicting a fixed proportion Proh of ROH of offspring; performing z-score standardization processing on the four genetic indexes: performing principal component analysis on standardized data, extracting the first two principal components PC1 and PC2, determining a weight according to a variance contribution rate, and calculating a pairing comprehensive score; and generating a pairing candidate recommendation list for each individual according to the comprehensive score, and screening a high-quality pairing scheme. The method disclosed by the invention can be completely independent of pedigree records, and genetic evaluation is directly carried out based on genome data.

Provided are a reagent combination or a kit for constructing an embryoid and the use thereof. The reagent combination or the kit can be used for inducing a stem cell to produce a blastocyst-like lineage precursor cell, a blastocyst-like cell and / or an embryoid, which are based on small-molecule induction and independent of transgenes, and have a single cell source. The produced blastocyst-like lineage precursor cell and blastocyst-like cell have a full blastocyst lineage, and are seed cells having balanced developmental competence and totipotency, which solves the problem of unbalanced cell maturation in the prior art. The produced embryoid is highly similar to natural embryos in terms of morphological characteristics and transcriptomic characteristics, has the capability of highly reproducing post-implantation embryonic development and / or gastrulation, which is beneficial for research on embryonic development in vitro. The method for inducing the stem cell to produce the blastocyst-like lineage precursor cell, the blastocyst-like cell and / or the embryoid by using the reagent combination or the kit is simple, and has high applicability and high embryoid construction efficiency.

Provided herein are systems of modulating gene expression, methods of use thereof, and cells engineered thereof for the purpose of differentiating cells, for example beta cells.

Provides herein is a method for identifying the specific cell lineage of cells in culture comprising the steps of determining from the nucleic acid molecules isolated from said recombinant cells in culture the presence of polymorphisms or SNPs at at least 5 different positions within at least five genes contained in said nucleic acid molecules, obtaining a genetic profile from the determination of the previous step, and identifying the cell lineage of said cells in culture from said genetic profile, and wherein the recombinant cells produce a recombinant protein.

An in vitro approach for detecting Enterovirus-D68 (EV-D68) is disclosed. In one aspect, two or more EV-D68 genomic regions are amplified with primers that each include a 5' universal tail and an EV-D68-specific sequence (SEQ ID NOs: 47-92). The tails enable indexing and sequencing of tiled amplicons to confirm EV-D68 presence and permit lineage or subclade assignment. In another aspect, a type-specific RT-qPCR assay employs a forward primer (SEQ ID NO: 95), a reverse primer (SEQ ID NO: 96), and a fluorescent probe (SEQ ID NO:97) for rapid detection. Primer sets and kits comprising the primers, probe, and optional reagents are provided for environmental, clinical, or research testing performed outside the body, including wastewater-based surveillance. The universal tails are selected to avoid sequence overlap with any target amplicon. The methods, uses, and kits support sensitive EV-D68 detection across circulating variants and facilitate scalable sequencing and public-health monitoring.

A DNA construct containing an erythroid lineage-specific promoter operably linked to a nucleotide coding sequence of interest and a method of using the same in the prevention or treatment a hematopoietic disorder such as a hemoglobinopathy are described.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The application discloses application of a genetic lineage tracing mouse model in regulation of myocardial cell transformation into osteoblasts, and belongs to the technical field of biotechnology.The tracing mouse model is induced to have myocardial calcification through high-dose steroids or myocardial infarction operation, the tracing mouse model expresses a label protein in myocardial cells of mammals, and the label protein expression in the myocardial cells is realized through a Cre / loxP system.The genetic lineage tracing mouse model provided by the application can be used for detecting myocardial cell transformation into osteoblasts, and can also be used for developing or screening drugs capable of preventing myocardial calcification or preparing products for developing or screening the drugs capable of preventing myocardial calcification.

The invention discloses a marker combination for thyroid nodule risk assessment and application thereof. Based on large-sample multi-omics sequencing data, papillary thyroid carcinoma (PTC) and benign nodules are found to have a common epithelial spectrum origin, epithelial intermediate state cells (EICs) with malignant potential are found in the benign nodules, and typical molecular markers of the EICs are further identified to comprise ZCCHC12, CDLN1 and NPC2. The three genes participate in proliferation and differentiation of cells, the expression in PTC is remarkably up-regulated, and the malignant risk of the benign thyroid nodules can be evaluated by detecting the expression level of the markers in a biological sample. According to the method, a means for recognizing the high-risk benign nodules before malignant transformation occurs is provided for the first time, risk perspectiveness is achieved, and higher specificity and sensitivity are possibly achieved for recognizing the benign nodules with malignant potential.

The identification of differentiation stages, differentiation trajectories, and expression profiles of hematopoietic progenitor cells and fate-determining factors, and the application thereof are provided. The enrichment and identification of rare hematopoietic progenitor cells, as well as the identification of and their fate-determining genes, are also provided. A method for reconstructing hematopoietic hierarchy is provided, which includes fate-determining factors, differentiation trajectories, and patterns within lineage commitment processes.

The invention provides a method for preventing or treating diseases related to CSNK2B gene deletion. The disclosure also provides a CSNK2B protein or a variant thereof, a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, an expression cassette comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a vector comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a virus, such as an AAV particle, expressing a CSNK2B protein or a variant thereof, and a method for preparing the CSNK2B protein or a variant thereof. According to the present invention, the use of the cells expressing the CSNK2B protein in the preparation of drugs for treating or preventing CSNK2B gene deletion-related diseases in subjects is provided, and the CSNK2B gene deletion-related diseases are selected from the group consisting of Rett syndrome, autism spectrum disorder (ASD), Porier-Bienvenu neurodevelopment syndrome (POBINDS), epilepsy or broad-spectrum development retardation, or the use of the cells expressing the CSNK2B protein in the preparation of the drugs for treating or preventing the CSNK2B gene deletion-related diseases in the subjects,

The invention belongs to the technical field of molecular markers, and particularly relates to a group of SNP (Single Nucleotide Polymorphism) molecular markers for genetic analysis of hypoxia genes of Himalayan marmots and application of the SNP molecular markers. The SNP molecular marker comprises one or more than two of 11 SNP loci which are all located in an amplified fragment of a Himalayan marmot EPO gene with a nucleotide sequence as shown in SEQ ID NO.1, molecular technical support is provided for Himalayan marmot population genetics research, and the SNP molecular marker can be used for research on Himalayan marmot hypoxia adaptation, population evolution and the like. Moreover, the invention also provides a primer pair capable of identifying the SNP molecular marker, the primer pair can perform specific amplification on Himalayan marmot EPO hypoxia gene sequences of different geographical populations, has high polymorphism, can be applied to the research fields of Himalayan marmot environmental adaptation, genetic diversity, pedigree geography and the like, and has wide application prospects.

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

The invention relates to the field of bioinformatics, and provides a single cell pedigree tracing method. According to the technical scheme, single cell transcriptome sequencing is combined with Bulk DNA targeted sequencing, so that the cost of pure single cell transcriptome sequencing is reduced, and the accuracy of single cell labeling is ensured through a subsequent filtering method of reserving a unique bar code.

Provided herein are methods, compositions, systems, kits and uses for integrated, simultaneous spatial multiomic analyses of tissues and samples including chromatin accessibility epigenomic analysis, RNA expression transcriptomic analysis, cell cluster and cell lineage analysis, transcription factor motif analysis, extrachromosomal DNA analysis and mitochondrial DNA analysis.

The invention relates to the technical field of forest tree genetic breeding, and discloses a larch fast-growing breeding method and system based on gene marker-assisted selection, and the method comprises the following steps: constructing a larch phenotype-genotype data set and carrying out genetic association analysis to obtain fast-growing related gene markers, detecting seedling genotypes and calculating fast-growing potential indexes, and calculating an adaptability index by combining the pedigree information and the adaptability related genotype, judging a fast-growing grade according to the fast-growing potential index and the adaptability index, and generating a breeding selection list of fast-growing optimization, regional trial planting and elimination types. According to the method, gene marker detection, additive effect calculation and regional adaptability analysis are integrated into a unified quantitative evaluation system, so that efficient screening and accurate classification of the larch fast-growing seedlings are realized, the breeding efficiency is remarkably improved, and the breeding period is shortened.

Aspects of the present disclosure relate to expression cassettes encoding miniShank3 proteins, AAV vectors containing the expression cassettes, and gene therapy methods, particularly where the expression cassettes are formulated to further contain an AAV9 capsid, and the gene therapy is useful for treating neurodevelopmental disorders such as autism spectrum disorder (ASD) and Phelan-McDermid syndrome.

Provided is an embryo model, which is obtained by means of self-assembly of induced pluripotent stem cells and induced hypoblast stem cells, wherein both the induced pluripotent stem cells and the induced hypoblast stem cells are obtained by means of somatic cell reprogramming. The self-assembly of the stem cells of two different lineages generated by means of somatic cell reprogramming forms an embryo model simulating human peri-gastrulation. The embryo model better reproduces the interaction and communication mechanism among cells of multiple lineages during human embryonic development by means of combining cells of different lineages. With the embryo model, by means of a gene editing tool, lineage tracing and gene regulatory network research can be performed on cells of different lineages, thereby enabling an in-depth understanding of the molecular regulatory mechanisms of early human embryonic development.

This invention discloses a method and system for single-cell transcriptome cell type annotation based on deep learning, belonging to the field of bioinformatics data processing technology. The method includes five steps: data quality control preprocessing, Transformer cell encoder pre-training, graph attention network cell relationship modeling, hierarchical classification annotation, and zero-shot transfer annotation. This invention deeply couples Transformer representation learning with graph attention networks, obtains general representations through masked gene prediction pre-training, enhances rare cell type features using KNN graphs and graph attention message passing, improves recognition accuracy by adopting a hierarchical classification architecture from main lineage to subtype, and supports zero-shot cross-modal annotation based on text description.

The application discloses a primer group, a kit and application for screening autism spectrum disorder patients, and belongs to the field of disease diagnosis. The technical problem solved by the application is how to screen autism spectrum disorder patients in Chinese Han population. The primer group for screening autism spectrum disorder patients disclosed by the application is directed to 132 autism susceptible gene sites, and is composed of 264 single-stranded DNAs shown in SEQ ID No. 1 to SEQ ID No. 264. According to the 132 autism susceptible gene sites, a data model is established by SVM, autism spectrum disorder patients can be screened, and the data model has good accuracy, precision, recall rate, F1 score and AUC value, can provide stable and efficient prediction performance between balanced precision and recall rate, and has strong ability in distinguishing autism spectrum disorder patients and healthy individuals.

The present disclosure relates to compositions and methods for modulating signaling in a cell and / or for differentiating / maturing a cell. Compositions of this disclosure, as may be used in associated methods, may include first and second segments that are connected to one another. When used in methods to differentiate and / or mature immune cells, compositions of this disclosure advantageously increase frequency and yields of arising cells in comparison to conditions deploying only first or second segments separately, or both individually (not connected).

The invention relates to a method for diagnosis, disease monitoring and / or therapy guidance in a patient suspected of having a neurodegenerative disease of the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis-spectrum (FTD-ALS-spectrum), comprising (a.) providing a sample obtained from said patient, wherein said sample comprises extracellular vesicles, (b.) determining a level of one or more FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, (c.) wherein the level of the one or more biomarkers is indicative of whether the patient has (and / or allows to distinguish between) a neurodegenerative disease of the FTD-ALS-spectrum comprising a Tau-proteinopathy or a neurodegenerative disease of the FTD-ALS-spectrum comprising a TAR DNA-binding protein 43 (TPD-43)-proteinopathy. The invention further relates to a kit for carrying out the method of the present invention, methods of treating patients identified using the method of the invention, methods of determining said FTD-ALS-spectrum biomarkers in the extracellular vesicles of said sample, and samples comprising extracellular vesicles and said FTD-ALS-spectrum biomarkers.

The application discloses a high-precision and high-coverage pedigree tree tracking method, and relates to the technical field of cell pedigree tracking, and specifically comprises the following steps: selecting single-direction RNA1, single-direction RNA2, single-direction RNA3 and single-direction RNA4 which are completely different in sequence as backups, and selecting single-cell clone amplification to prepare a pedigree barcode with 13 editing sites as a backup; and adopting a cell pedigree barcode technology to match the single-direction RNA1, the single-direction RNA2, the single-direction RNA3 and the single-direction RNA4 with the 13 editing sites of the pedigree barcode respectively. The high-precision and high-coverage pedigree tree tracking method increases the average expression amount of the pedigree barcode in all cells, reduces the speed of consumption of the editing sites, increases the traceable time, simultaneously reduces the proportion of cross-site deletion mutations, and obtains a high proportion of single leaves of a cell pedigree tree, so that a pedigree tree determination method with a single-cell level resolution is realized, and the mortality of cells in clone amplification and the loss rate in cell digestion are reduced.

The invention belongs to the field of medicine, and provides a complete grape embryo-derived human trophoblast stem cell line and application thereof. The preservation number of the human trophoblast stem cell line is CGMCC No.C2024411, and the human trophoblast stem cell line can be induced and differentiated into a syncytial trophoblast and an extravillus trophoblast, can simulate differentiation and development defects of a grape embryo trophoblast pedigree, can be applied as an in-vitro research model of a complete grape embryo, and has a wide application prospect in drug target research and genetic research.

A bioinformatic system that differentiates collections of shared autosomal DNA (atDNA) matches is disclosed. The invention consists of two main parts: a process which can differentiate “Favourable” Trios of individuals from “Unfavourable” Trios, whilst doing so in a computationally efficient manner, compatible with real-time reporting of DNA testing results; and a desktop / spreadsheet prototype which performs a bioinformatic assessment of three individuals using the matches from their DNA test results by utilizing the aforementioned process. The process may also be applied to assess larger (n-element) collections of individuals, to verify the integrity of datasets produced by other bioinformatic processes, to validate collections of DNA matches used as inputs to bioinformatic processes, and to assess the integrity of ancestral lines connecting individuals of unknown or uncertain pedigree within the context of established family groupings.

The present application relates to the technical field of medicine. Disclosed for the first time is a chemogenetic gene therapy technology for treating autism spectrum disorder. Specifically, provided in the present technology is a combined drug treatment strategy, which comprises a neuron-targeted intracranial injection and a small-molecule agonist (the latter serving as a second drug administered after surgery). According to this strategy, the injection is precisely delivered to the posterior substantia innominata brain region by means of stereotactic intracranial injection, and then the second drug is administered after surgery, so as to intervene in the social behavioral abnormalities associated with autism spectrum disorder. The therapy can prolong the attack latency, shorten the duration of aggressive behaviors, and reduce the frequency of aggressive episodes in model animals, while not interfering with basic vital activities and emotional states such as normal social interaction, fear and anxiety. This strategy pioneers a novel approach for treating autism spectrum disorder, which is expected to improve the quality of life of patients and alleviate the burdens on the families thereof and society, and thus has broad prospects for clinical application.

Compositions, methods, and kits are provided for detecting pre-malignant and cancerous cells having lineage plasticity and drug resistance. Also provided are methods of screening candidate agents for efficacy in switching pre-malignant or cancerous cells, identified as being in a cell state having lineage plasticity and drug resistance, to a non-drug resistant proliferative cell state that can be treated with anti-mitotic therapeutic agents.